NKGen Biotech, Inc.

NKGen Biotech [Nasdaq:NKGN] will present new biomarker data on SNK01 in Alzheimer’s disease on July 30, 2024, at the upcoming Alzheimer’s Association International Conference (AAIC) in Philadelphia, PA. NKGen will present data on SNK01’s ability to reduce α-synuclein in Alzheimer’s patients, which is significant given that α-synuclein has been shown to correlate with worse cognitive function in Alzheimer’s disease. See press release at link below for more information. #nkcelltherapy #celltherapy #Alzheimers #AlzheimersDisease #nkgenbiotech #immunotherapy $NKGN

NKGen [Nasdaq: NKGN] is pleased to announce the appointment of Marco Gottardis, PhD to the NKGen Biotech Board of Directors. See press release at link below for more information. #nkgenbiotech #nkcelltherapy #celltherapy #boardmembers $NKGN

NKGen Biotech's [Nasdaq:NKGN] groundbreaking research in Alzheimer's disease was featured on KCBS/KCAL News last night! Witness the impactful results from our clinical trial patients firsthand as they share their remarkable progress. Don't miss this exclusive news segment highlighting the important work that we do for patients at NKGen Biotech. $NKGN #nkcelltherapy #celltherapy #alzheimers #clinicaltrials #nkgenbiotech #alzheimersdisease

We are excited to announce that NKGen will be featured in a news story tomorrow, June 25th, on KCBS-TV/KCAL-TV during the 11:00 pm News Broadcast. The segment will highlight our Phase 1/2a Alzheimer’s clinical trial progress. Tune in to learn more about the groundbreaking work we are doing to develop innovative disease-modifying treatments for Alzheimer's disease. #nkcelltherapy #celltherapy #alzheimers #nkgenbiotech

Alzheimer's News Today article highlights our Phase 2 Alzheimer's trial. We are currently in the process of recruiting patients with moderate Alzheimer's disease (NCT06189963).

NKGen's CEO, Dr. Paul Y. Song, MD, presented updated Phase 1 data on SNK02 allogeneic NK cell therapy in solid tumors and discussed the benefits of eliminating pre-treatment lymphodepletion in patients undergoing SNK02 therapy, aiming to safeguard immune function and aid in recovery, at the 6th Annual Allogeneic Cell Therapies Summit. #nkcelltherapy #celltherapy #immunooncology #oncology #nkgenbiotech

NKGen CEO, Dr. Paul Y. Song MD, will be presenting at the Allogeneic Cell Therapies Summit on July 12, 2024, at 12:00 pm ET in Boston, MA. Dr. Song will be discussing NKGen’s novel SNK02 allogeneic blood-derived NK cell therapy commercial manufacturing and cryopreservation process along with an update on the SNK02 Phase 1 clinical trial results in refractory solid tumors. See press release at link below for more information. #nkgenbiotech #nkcelltherapy #celltherapy #allogeneic #immunooncology #immunotherapy #oncology

June is Alzheimer's & Brain Awareness Month. Join us in raising awareness of the need for new treatment options for the over 55 million people worldwide living with AD and other dementia. https://bit.ly/3BUtmrT #AlzheimersAwareness #BrainHealth #EndAlz

NKGen CEO, Paul Y. Song, MD joined a panel of experts and the Medicine Maker to discuss the top prospects for the treatment of Alzheimer's disease, including our autologous NK cell therapy, SNK01. Read here: https://bit.ly/3yBpbmo #Alzheimersdisease #NKCellTherapy

In the Phase 1 trial, the best objective response of stable disease was demonstrated in 100% of patients that completed 8 treatment cycles of SNK02. SNK02 was well tolerated as a monotherapy and appears to have some clinical activity against pretreated solid tumors despite the lack of lymphodepletion. More details: https://bit.ly/3UOyF5k #ASCO24 #NKCellTherapy